Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/biom7030053 http://scihub22266oqcxt.onion/10.3390/biom7030053 C5618234!5618234!28696357     free     free     free       Biomolecules 2017 ; 7 (3): ä Nephropedia Template TP {{tp|p=28696357|t=2017. MYC-Driven Pathways in Breast Cancer Subtypes |pdf=|usr=}}{{28696357}} gab.com Text MYC-Driven Pathways in Breast Cancer Subtypes JO: Biomolecules http://www.kidney.de/pget.php?&tw=1&pmid=28696357 #FOAvip The transcription factor MYC (MYC proto-oncogene, bHLH transcription factor) is an essential signaling hub in multiple cellular processes that sustain growth of many types of cancers. MYC regulates expression of RNA, both protein and non-coding, that control central metabolic pathways, cell death, proliferation, differentiation, stress pathways, and mechanisms of drug resistance. Activation of MYC has been widely reported in breast cancer progression. Breast cancer is a complex heterogeneous disease and treatment options are primarily guided by histological and biochemical evaluations of the tumors. Based on biochemical markers, three main breast cancer categories are ER+ (estrogen receptor alpha positive), HER2+ (human epidermal growth factor receptor 2 positive), and TNBC (triple-negative breast cancer; estrogen receptor negative, progesterone receptor negative, HER2 negative). MYC is elevated in TNBC compared with other cancer subtypes. Interestingly, MYC-driven pathways are further elevated in aggressive breast cancer cells and tumors that display drug resistant phenotype. Identification of MYC target genes is essential in isolating signaling pathways that drive tumor development. In this review, we address the role of MYC in the three major breast cancer subtypes and highlight the most promising leads to target MYC functions. Twit Text FOAVip MYC-Driven Pathways in Breast Cancer Subtypes ????Biomolecules http://www.kidney.de/pget.php?&tw=1&pmid=28696357 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28696357 #FOAvip English Wikipedia <ref>{{Cite pmid|28696357}}</ref> MYC-Driven Pathways in Breast Cancer Subtypes #MMPMID28696357 Fallah Y; Brundage J; Allegakoen P; Shajahan-Haq AN Biomolecules 2017[Sep]; 7 (3): ä PMID28696357show ga The transcription factor MYC (MYC proto-oncogene, bHLH transcription factor) is an essential signaling hub in multiple cellular processes that sustain growth of many types of cancers. MYC regulates expression of RNA, both protein and non-coding, that control central metabolic pathways, cell death, proliferation, differentiation, stress pathways, and mechanisms of drug resistance. Activation of MYC has been widely reported in breast cancer progression. Breast cancer is a complex heterogeneous disease and treatment options are primarily guided by histological and biochemical evaluations of the tumors. Based on biochemical markers, three main breast cancer categories are ER+ (estrogen receptor alpha positive), HER2+ (human epidermal growth factor receptor 2 positive), and TNBC (triple-negative breast cancer; estrogen receptor negative, progesterone receptor negative, HER2 negative). MYC is elevated in TNBC compared with other cancer subtypes. Interestingly, MYC-driven pathways are further elevated in aggressive breast cancer cells and tumors that display drug resistant phenotype. Identification of MYC target genes is essential in isolating signaling pathways that drive tumor development. In this review, we address the role of MYC in the three major breast cancer subtypes and highlight the most promising leads to target MYC functions. äMYC-Driven Pathways in Breast Cancer Subtypes (epmc).pdf DeepDyve Pubget Overpricing